26 January 2010, Lelystad, The Netherlands - Institut Mérieux will sponsor efforts by the TuBerculosis Vaccine Initiative (TBVI) to develop new vaccines and enhanced adjuvants and discover new biomarkers.
Institut Mérieux, a nonprofit organization, supports an integrated European network of more than 40 universities, institutes and industries involved in research and development of TB vaccines. Through its companies (bioMérieux for diagnostics and Transgene for immunotherapy) Institut Mérieux is seeking innovations, in particular to fight HIV, hepatitis and tuberculosis. In partnership with Fondation Mérieux, it is developing a multidisciplinary programme in the field of tuberculosis.
TBVI raises funds for research and development of new vaccines from governments, the European Union, companies and private funders.